Takeda gives EVP the reins at new subsidiary Nycomed; Indonesia's Kalbe taps deal-scouting team;

@FiercePharma:  AstraZeneca settles Seroquel patent suit, giving Handa license to launch copycat drug in 2016 $AZN #pharma. Report | Follow @FiercePharma

> Takeda Pharmaceutical has wrapped up its €9.6 billion buyout of the Swiss drugmaker Nycomed and named its own EVP, Dr. Frank Morich, as CEO of the new wholly owned subsidiary. Report

> Indonesia's Kalbe Farma, the largest drugmaker in Southeast Asia, has formed an M&A scouting team to look for deals in the region, some in consumer healthcare. News

> Pfizer ($PFE) is teaming up with a pharmacy standards group on an educational campaign to warn patients about counterfeit prescription drugs. Story

> A U.S. District Judge has sent an OxyContin liability suit back to Kentucky, where it was originally filed by the state attorney general; Purdue Pharma had originally petitioned for the jurisdictional move. Article

> Sanofi ($SNY) sold $1 billion of senior unsecured notes maturing 2014 at a yield of 1.242%. Item

> Pfizer spent $3.6 million on lobbying the federal government during the second quarter focusing on patent issues, drug shortages and healthcare reform implementation. Report

> Merck ($MRK) spent $1.1 million on lobbying during the second quarter--a 19% increase from the same period last year--as it focused on healthcare reform implementation and taxes. More

> Bristol-Myers Squibb ($BMY) spent $560,000 during the second quarter on lobbying the federal government, down from $980,000 year-over-year. Piece

Biotech News

@FierceBiotech: Most read on FierceBiotech this week: FDA readies release of long-awaited rules on biosimilars. Story | Follow @FierceBiotech

 @ JohnCFierce: I think next year I will do two Fierce 15s, one for Europe, one for the U.S. Follow @JohnCFierce

@RyanMFierce: Geron has new CEO to lead through first-ever US trial of embryonic stem cell therapy. News | Follow @RyanMFierce

 @MaureenFierce: Google AdWords ban keeps drug savings from U.S. poor. Article | Follow @MaureenFierce

> Cubist green lights Ph3 program against lethal diarrhea. Item

> J&J and Bayer's Xarelto wins where Pfizer drug lost. Article

> AstraZeneca flunks Ph2 lung cancer trial with drug from Array BioPharma. Report

And Finally... Twitter study maps users' mood cycles. Report